New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma.

Subjects

Subjects :

Adenocarcinoma drug therapy
Adenocarcinoma enzymology
Adenocarcinoma genetics
Biopsy
DNA Mutational Analysis
Humans
Imidazoles administration & dosage
Imidazoles adverse effects
Immunohistochemistry
MAP Kinase Kinase Kinases metabolism
Male
Melanoma enzymology
Melanoma genetics
Middle Aged
Molecular Targeted Therapy
Oximes administration & dosage
Oximes adverse effects
Pancreatic Neoplasms drug therapy
Pancreatic Neoplasms enzymology
Pancreatic Neoplasms genetics
Positron-Emission Tomography
Predictive Value of Tests
Protein Kinase Inhibitors administration & dosage
Protein Kinase Inhibitors adverse effects
Proto-Oncogene Proteins B-raf genetics
Proto-Oncogene Proteins B-raf metabolism
Proto-Oncogene Proteins p21(ras)
Pyridones administration & dosage
Pyridones adverse effects
Pyrimidinones administration & dosage
Pyrimidinones adverse effects
Risk Factors
Skin Neoplasms enzymology
Skin Neoplasms genetics
Time Factors
Tomography, X-Ray Computed
Treatment Outcome
Adenocarcinoma chemically induced
Antineoplastic Combined Chemotherapy Protocols adverse effects
MAP Kinase Kinase Kinases antagonists & inhibitors
Melanoma drug therapy
Melanoma secondary
Mutation
Pancreatic Neoplasms chemically induced
Proto-Oncogene Proteins genetics
Proto-Oncogene Proteins B-raf antagonists & inhibitors
Skin Neoplasms drug therapy
Skin Neoplasms pathology
ras Proteins genetics

Details

Language :

English

ISSN :

1527-7755

Volume :

33

Issue :

11

Database :

MEDLINE

Journal :

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

24821886

Full Text :

https://doi.org/10.1200/JCO.2013.51.5783